BIIB · Categories · Upgrades
BIIB - Analyst upgrades
Biogen Inc. (BIIB) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for BIIB
- Biogen upgraded by Needham with a new price targetNeedham upgraded Biogen from Hold to Buy and set a new price target of $255.00
- Biogen upgraded by UBS with a new price targetUBS upgraded Biogen from Neutral to Buy and set a new price target of $225.00
- Biogen upgraded by Wells Fargo with a new price targetWells Fargo upgraded Biogen from Equal Weight to Overweight and set a new price target of $250.00
- Biogen upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Biogen from Neutral to Overweight and set a new price target of $214.00
- Biogen upgraded by Stifel with a new price targetStifel upgraded Biogen from Hold to Buy and set a new price target of $202.00
- Biogen upgraded by Raymond James with a new price targetRaymond James upgraded Biogen from Mkt Perform to Outperform and set a new price target of $283.00
- Biogen upgraded by Guggenheim with a new price targetGuggenheim upgraded Biogen from Neutral to Buy and set a new price target of $350.00 from $270.00 previously
- Biogen upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Biogen from Neutral to Overweight and set a new price target of $346.00 from $280.00 previously
- Biogen upgraded by Goldman with a new price targetGoldman upgraded Biogen from Neutral to Buy and set a new price target of $370.00 from $220.00 previously
- Biogen upgraded by Stifel with a new price targetStifel upgraded Biogen from Hold to Buy and set a new price target of $299.00 from $223.00 previously
- Biogen upgraded by Argus with a new price targetArgus upgraded Biogen from Hold to Buy and set a new price target of $300.00
- Biogen upgraded by BMO Capital Markets with a new price targetBMO Capital Markets upgraded Biogen from Market Perform to Outperform and set a new price target of $360.00 from $217.00 previously
- Biogen upgraded by Robert W. Baird with a new price targetRobert W. Baird upgraded Biogen from Neutral to Outperform and set a new price target of $340.00 from $224.00 previously
- Biogen upgraded by Mizuho with a new price targetMizuho upgraded Biogen from Neutral to Buy and set a new price target of $270.00 from $207.00 previously
- Biogen upgraded by Wells Fargo with a new price targetWells Fargo upgraded Biogen from Equal Weight to Overweight and set a new price target of $265.00 from $235.00 previously
- Biogen upgraded by RBC Capital with a new price targetRBC Capital upgraded Biogen from Sector Perform to Outperform and set a new price target of $248.00 from $227.00 previously
- Biogen upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Biogen from Neutral to Overweight and set a new price target of $450.00 from $384.00 previously
- Biogen upgraded by Bernstein with a new price targetBernstein upgraded Biogen from Mkt Perform to Outperform and set a new price target of $500.00
- Biogen upgraded by UBS with a new price targetUBS upgraded Biogen from Neutral to Buy and set a new price target of $463.00
- Biogen upgraded by UBSUBS upgraded Biogen from Neutral to Buy
- Biogen upgraded by William BlairWilliam Blair upgraded Biogen from Mkt Perform to Outperform
- Biogen upgraded by Baird with a new price targetBaird upgraded Biogen from Underperform to Neutral and set a new price target of $382.00 from $216.00 previously
- Biogen upgraded by Robert W. Baird with a new price targetRobert W. Baird upgraded Biogen from Underperform to Neutral and set a new price target of $382.00 from $216.00 previously
- Biogen upgraded by Atlantic Equities with a new price targetAtlantic Equities upgraded Biogen from Underweight to Neutral and set a new price target of $415.00
- Biogen upgraded by Citigroup with a new price targetCitigroup upgraded Biogen from Sell to Neutral and set a new price target of $440.00 from $200.00 previously
- Biogen upgraded by Raymond JamesRaymond James upgraded Biogen from Underperform to Mkt Perform
- Biogen upgraded by Cowen with a new price targetCowen upgraded Biogen from Market Perform to Outperform and set a new price target of $450.00 from $225.00 previously
- Biogen upgraded by BofA Securities with a new price targetBofA Securities upgraded Biogen from Underperform to Neutral and set a new price target of $400.00 from $235.00 previously
- Biogen upgraded by Stifel with a new price targetStifel upgraded Biogen from Hold to Buy and set a new price target of $358.00 from $258.00 previously